Although endocrine therapy using selective estrogen receptor modulators (SERMs), such as Fulvestrant, has improved treatment outcomes for estrogen receptor-positive (ER+) breast cancer, drug resistance and tumor recurrence remain significant challenges. This evidence concerns the gene ESR1 and breast carcinoma.